NASDAQ:MLYS Mineralys Therapeutics (MLYS) Stock Price, News & Analysis $40.81 -1.23 (-2.93%) Closing price 10/23/2025 04:00 PM EasternExtended Trading$39.76 -1.05 (-2.56%) As of 08:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Mineralys Therapeutics Stock (NASDAQ:MLYS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Mineralys Therapeutics alerts:Sign Up Key Stats Today's Range$40.42▼$42.2450-Day Range$14.47▼$44.1652-Week Range$8.24▼$44.80Volume771,802 shsAverage Volume1.35 million shsMarket Capitalization$2.71 billionP/E RatioN/ADividend YieldN/APrice Target$43.50Consensus RatingModerate Buy Company Overview Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania. Read More Mineralys Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreMLYS MarketRank™: Mineralys Therapeutics scored higher than 49% of companies evaluated by MarketBeat, and ranked 624th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.8 / 5Analyst RatingModerate Buy Consensus RatingMineralys Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 5 buy ratings, 1 hold rating, and 1 sell rating.Upside/DownsideThe consensus price target for Mineralys Therapeutics is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageMineralys Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Mineralys Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Mineralys Therapeutics are expected to decrease in the coming year, from ($4.23) to ($4.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mineralys Therapeutics is -11.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mineralys Therapeutics is -11.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMineralys Therapeutics has a P/B Ratio of 10.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Mineralys Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted13.60% of the float of Mineralys Therapeutics has been sold short.Short Interest Ratio / Days to CoverMineralys Therapeutics has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Mineralys Therapeutics has recently decreased by 9.23%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMineralys Therapeutics does not currently pay a dividend.Dividend GrowthMineralys Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted13.60% of the float of Mineralys Therapeutics has been sold short.Short Interest Ratio / Days to CoverMineralys Therapeutics has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Mineralys Therapeutics has recently decreased by 9.23%, indicating that investor sentiment is improving significantly. News and Social Media2.2 / 5News Sentiment1.00 News SentimentMineralys Therapeutics has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Mineralys Therapeutics this week, compared to 6 articles on an average week.Search InterestOnly 5 people have searched for MLYS on MarketBeat in the last 30 days. This is a decrease of -58% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Mineralys Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership5.0 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Mineralys Therapeutics insiders have bought 1,316.90% more of their company's stock than they have sold. Specifically, they have bought $44,999,978.00 in company stock and sold $3,175,946.00 in company stock.Percentage Held by Insiders25.56% of the stock of Mineralys Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.46% of the stock of Mineralys Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Mineralys Therapeutics' insider trading history. Receive MLYS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mineralys Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MLYS Stock News HeadlinesDavid Malcom Rodman Sells 10,369 Shares of Mineralys Therapeutics (NASDAQ:MLYS) StockOctober 16, 2025 | insidertrades.comMineralys Therapeutics Announces Late-Breaking Presentation of Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 2025October 21 at 8:00 AM | globenewswire.comMy starkest warning in years Porter Stansberry — founder of one of the world’s largest financial research firms — believes we’re entering a historic economic shift he calls The Final Displacement. Backed by warnings from Nobel Prize winners, this rare event could reshape everything from markets to personal wealth, just as past global displacements toppled empires and created new fortunes. His new investigation reveals why it’s unfolding now, what’s driving it, and how to position yourself on the right side of history.October 24 at 2:00 AM | Porter & Company (Ad)Mineralys Completes Enrollment in Phase 2 Sleep Apnea and Hypertension TrialOctober 5, 2025 | msn.comWhy Mineralys Therapeutics (MLYS) Is Up 5.1% After Completing Enrollment in EXPLORE-OSA Hypertension TrialOctober 3, 2025 | finance.yahoo.comMineralys: Lorundrostat Continues To Deliver Hypertension Market ExpansionsOctober 1, 2025 | seekingalpha.comMineralys Therapeutics, Inc. (MLYS) Shows Positive Phase 3 HTN Results, Blood Pressure Drops in High-Risk GroupsSeptember 30, 2025 | insidermonkey.comMineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and HypertensionSeptember 30, 2025 | globenewswire.comSee More Headlines MLYS Stock Analysis - Frequently Asked Questions How have MLYS shares performed this year? Mineralys Therapeutics' stock was trading at $12.31 at the start of the year. Since then, MLYS shares have increased by 231.5% and is now trading at $40.81. How were Mineralys Therapeutics' earnings last quarter? Mineralys Therapeutics, Inc. (NASDAQ:MLYS) posted its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.78) by $0.12. Read the conference call transcript. When did Mineralys Therapeutics IPO? Mineralys Therapeutics (MLYS) raised $180 million in an initial public offering on Friday, February 10th 2023. The company issued 12,000,000 shares at $14.00-$16.00 per share. Who are Mineralys Therapeutics' major shareholders? Mineralys Therapeutics' top institutional investors include Swedbank AB (0.45%), Simplify Asset Management Inc. (0.33%), Voya Investment Management LLC (0.21%) and SG Americas Securities LLC (0.15%). Insiders that own company stock include Brian Taylor Slingsby, Samsara Biocapital Gp, Llc, Ra Capital Management, LP, Hbm Healthcare Investments (Ca, Jon Congleton, Adam Scott Levy and David Malcom Rodman. View institutional ownership trends. How do I buy shares of Mineralys Therapeutics? Shares of MLYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Mineralys Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mineralys Therapeutics investors own include Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX) and Alphabet (GOOG). Company Calendar Last Earnings8/12/2025Today10/24/2025Next Earnings (Estimated)11/10/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MLYS CIK1933414 Webwww.mineralystx.com Phone888-378-6240FaxN/AEmployees28Year FoundedN/APrice Target and Rating Average Price Target for Mineralys Therapeutics$43.50 High Price Target$52.00 Low Price Target$26.00 Potential Upside/Downside+6.6%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($3.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$177.81 million Net MarginsN/A Pretax MarginN/A Return on Equity-70.44% Return on Assets-65.51% Debt Debt-to-Equity RatioN/A Current Ratio15.12 Quick Ratio15.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.84 per share Price / Book10.63Miscellaneous Outstanding Shares66,290,000Free Float49,350,000Market Cap$2.71 billion OptionableOptionable Beta0.40 The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:MLYS) was last updated on 10/24/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredApple's secret partnerThe Tiny Company Apple Can’t Live Without A tiny company holds the key to Apple’s biggest breakthrough sinc...The Oxford Club | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...Brownstone Research | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredGold surges past $4,200 … but this has beat gold by 1,000xGold has surged past $4,200 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mineralys Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mineralys Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.